[{"NetIncomeLoss_1_Q3_USD":39500000.0,"OperatingLeaseExpense_1_Q3_USD":200000.0,"OperatingLeaseExpense_3_Q3_USD":800000.0,"AssetsCurrent_0_Q3_USD":958800000.0,"ProceedsFromIssuanceOfSeniorLongTermDebt_3_Q3_USD":450000000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-115000000.0,"EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_1_Q3_USD":3300000.0,"EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3_Q3_USD":9900000.0,"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3_Q3_shares":1100000.0,"IncomeTaxesPaid_3_Q3_USD":87300000.0,"OperatingCostsAndExpenses_1_Q3_USD":323900000.0,"OperatingCostsAndExpenses_3_Q3_USD":796700000.0,"InterestPaidNet_3_Q3_USD":14000000.0,"BilledContractReceivables_0_Q3_USD":166000000.0,"OperatingLeaseRightOfUseAssetAmortizationExpense_1_Q3_USD":1100000.0,"OperatingLeaseRightOfUseAssetAmortizationExpense_3_Q3_USD":3200000.0,"InventoryFinishedGoodsNetOfReserves_0_Q3_USD":49000000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":-21400000.0,"IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1_Q3_shares":1300000.0,"LongTermDebt_0_Q3_USD":891100000.0,"LongTermDebtCurrent_0_Q3_USD":30900000.0,"ShareBasedCompensation_3_Q3_USD":41000000.0,"Assets_0_Q3_USD":2616300000.0,"InventoryWorkInProcessNetOfReserves_0_Q3_USD":104300000.0,"CommonStockSharesIssued_0_Q3_shares":54200000.0,"TreasuryStockValue_0_Q3_USD":39600000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q3_USD":12400000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_3_Q3_USD":54800000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q3_shares":0.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":0.0,"TreasuryStockShares_0_Q3_shares":1200000.0,"CostOfGoodsAndServicesSold_1_Q3_USD":149000000.0,"CostOfGoodsAndServicesSold_3_Q3_USD":355700000.0,"ContractWithCustomerLiability_0_Q3_USD":79900000.0,"PaymentsForPreviousAcquisition_3_Q3_USD":10000000.0,"SellingGeneralAndAdministrativeExpense_1_Q3_USD":75500000.0,"SellingGeneralAndAdministrativeExpense_3_Q3_USD":221200000.0,"OtherNoncashIncomeExpense_3_Q3_USD":-600000.0,"RestrictedCashCurrent_0_Q3_USD":200000.0,"AccruedLiabilitiesCurrent_0_Q3_USD":34900000.0,"OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_1_Q3_USD":0.0,"OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_3_Q3_USD":0.0,"ProceedsFromLinesOfCredit_3_Q3_USD":0.0,"RepaymentsOfLinesOfCredit_3_Q3_USD":373000000.0,"CommonStockValue_0_Q3_USD":100000.0,"IncomeTaxExpenseBenefit_1_Q3_USD":15500000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":34700000.0,"AccountsReceivableNetCurrent_0_Q3_USD":196100000.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":1300000.0,"OtherNonoperatingIncomeExpense_3_Q3_USD":1300000.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":4400000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":54300000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":53600000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_Q3_USD":-500000.0,"EarningsPerShareBasic_1_Q3_USD":0.75,"EarningsPerShareBasic_3_Q3_USD":2.28,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q3_USD":154000000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":84400000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":175000000.0,"DepreciationDepletionAndAmortization_3_Q3_USD":85600000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":23400000.0,"RevenueRemainingPerformanceObligation_0_Q3_USD":2200000000.0,"IncreaseDecreaseInEmployeeRelatedLiabilities_3_Q3_USD":14500000.0,"MoneyMarketFundsAtCarryingValue_0_Q3_USD":290800000.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"OperatingLeaseLiability_0_Q3_USD":25100000.0,"Liabilities_0_Q3_USD":1364800000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":20700000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":415000000.0,"OtherAssetsNoncurrent_0_Q3_USD":106400000.0,"InventoryLIFOReservePeriodCharge_1_Q3_USD":13800000.0,"AmortizationOfIntangibleAssets_3_Q3_USD":44800000.0,"AmortizationOfIntangibleAssets_1_Q3_USD":15000000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":10600000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":40300000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":108200000.0,"IncreaseDecreaseInInventories_3_Q3_USD":47600000.0,"PaymentForContingentConsiderationLiabilityFinancingActivities_3_Q3_USD":2200000.0,"ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3_Q3_USD":29000000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":71800000.0,"EffectiveIncomeTaxRateContinuingOperations_3_Q3_pure":0.29,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.001,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.001,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":61800000.0,"PaymentsOfDebtIssuanceCosts_3_Q3_USD":8400000.0,"AccountsPayableCurrent_0_Q3_USD":102800000.0,"RepaymentsOfMediumTermNotes_3_Q3_USD":8400000.0,"LiabilitiesCurrent_0_Q3_USD":299300000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":53000000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":52500000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":290900000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q3_USD":-200000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3_Q3_USD":-600000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3_Q3_USD":12800000.0,"InventoryRawMaterialsAndSuppliesNetOfReserves_0_Q3_USD":116800000.0,"Goodwill_0_Q3_USD":266500000.0,"OperatingLeaseLeaseIncome_1_Q3_USD":18100000.0,"OperatingLeaseLeaseIncome_3_Q3_USD":18100000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q3_USD":800000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3_Q3_USD":-11500000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q3_USD":246900000.0,"NonoperatingIncomeExpense_3_Q3_USD":-21300000.0,"AmortizationOfFinancingCosts_3_Q3_USD":2400000.0,"NonoperatingIncomeExpense_1_Q3_USD":-6300000.0,"InterestExpense_1_Q3_USD":7600000.0,"NetIncomeLoss_3_Q3_USD":119700000.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":606500000.0,"BusinessCombinationContingentConsiderationLiabilityNoncurrent_0_Q3_USD":35200000.0,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_1_Q3_USD":-200000.0,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_3_Q3_USD":3400000.0,"CapitalExpendituresIncurredButNotYetPaid_3_Q3_USD":9700000.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"DeferredIncomeTaxLiabilitiesNet_0_Q3_USD":64000000.0,"NumberOfOperatingSegments_3_Q3_segment":1.0,"FiniteLivedIntangibleAssetsNet_0_Q3_USD":678100000.0,"AdditionalPaidInCapital_0_Q3_USD":770900000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q3_pure":0.042,"IntangibleAssetsNetExcludingGoodwill_0_Q3_USD":678100000.0,"LongTermDebtNoncurrent_0_Q3_USD":848500000.0,"ProceedsFromStockOptionsExercised_3_Q3_USD":26600000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":77400000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":415200000.0,"InterestExpense_3_Q3_USD":22600000.0,"EffectiveIncomeTaxRateReconciliationNondeductibleExpense_3_Q3_pure":0.25,"ContractWithCustomerLiabilityRevenueRecognized_3_Q3_USD":69000000.0,"EarningsPerShareDiluted_3_Q3_USD":2.23,"DeferredIncomeTaxExpenseBenefit_3_Q3_USD":-4400000.0,"PreferredStockValue_0_Q3_USD":0.0,"FiniteLivedIntangibleAssetsGross_0_Q3_USD":832100000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3_Q3_USD":2200000.0,"FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0_Q3_USD":58300000.0,"InventoryNet_0_Q3_USD":270100000.0,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1_Q3_USD":1000000.0,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3_Q3_USD":-10900000.0,"NotesPayableCurrent_0_Q3_USD":30900000.0,"AllowanceForDoubtfulAccountsReceivable_0_Q3_USD":700000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1_Q3_USD":55000000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3_Q3_USD":154400000.0,"OperatingIncomeLoss_1_Q3_USD":61300000.0,"OperatingIncomeLoss_3_Q3_USD":175700000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":385200000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":972400000.0,"CommonStockSharesAuthorized_0_Q3_shares":200000000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":2616300000.0,"EarningsPerShareDiluted_1_Q3_USD":0.73,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":76900000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":41000000.0,"CommonStockSharesOutstanding_0_Q3_shares":53000000.0,"IncreaseDecreaseInAccountsReceivable_3_Q3_USD":-74600000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":247200000.0,"LeaseCost_1_Q3_USD":1300000.0,"LeaseCost_3_Q3_USD":4000000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":541500000.0,"DeferredCostsCurrent_0_Q3_USD":40800000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":105000000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q3_USD":60400000.0,"StockholdersEquity_0_Q3_USD":1251500000.0,"OtherLiabilitiesCurrent_0_Q3_USD":53800000.0,"OtherLiabilitiesNoncurrent_0_Q3_USD":57400000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":4400000.0,"UnbilledContractsReceivable_0_Q3_USD":30100000.0,"DeferredFinanceCostsNoncurrentNet_0_Q3_USD":11700000.0,"PropertyPlantAndEquipmentGross_0_Q3_USD":853400000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":10000000.0,"PreferredStockSharesAuthorized_0_Q3_shares":15000000.0,"IncreaseDecreaseInContractWithCustomerLiability_3_Q3_USD":-9000000.0,"Ticker":"EBS","CIK":"1367644","name":"EMERGENT BIOSOLUTIONS INC.","OfficialName":"Emergent Biosolutions Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"2077670312.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20201106"}]